ALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1 Post published:April 13, 2023 Continue ReadingALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1
ALENTIS THERAPEUTICS makes key leadership appointments Post published:February 17, 2023 Continue ReadingALENTIS THERAPEUTICS makes key leadership appointments
Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1 Post published:January 9, 2023 Continue ReadingPositive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1
Alentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical Officer Post published:January 5, 2023 Continue ReadingAlentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical Officer
Preclinical data published in Science Translational Medicine provide proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs Post published:December 21, 2022 Continue ReadingPreclinical data published in Science Translational Medicine provide proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs
Alentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model Post published:December 1, 2022 Continue ReadingAlentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model
Alentis Therapeutics Announces Presentations at AASLD The Liver MeetingĀ® 2022 Post published:November 4, 2022 Continue ReadingAlentis Therapeutics Announces Presentations at AASLD The Liver MeetingĀ® 2022
Article published in The Journal of Hepatology highlights potential of Claudin-1 as a novel target for the treatment of hepatocellular carcinoma Post published:November 2, 2022 Continue ReadingArticle published in The Journal of Hepatology highlights potential of Claudin-1 as a novel target for the treatment of hepatocellular carcinoma
Swiss Innovation Agency to Co-fund Research Collaboration to Accelerate Discovery of Biomarkers for Fibrosis Post published:September 27, 2022 Continue ReadingSwiss Innovation Agency to Co-fund Research Collaboration to Accelerate Discovery of Biomarkers for Fibrosis